Low-Molecular-Weight Heparin as Bridging Anticoagulation During Interruption of Warfarin: Assessment of a Standardized Periprocedural Anticoagulation Regimen

Perspectives in Vascular Surgery and Endovascular Therapy

Volumn 17, Issue 2, 2005, Pages 176-177

  D'addio, Victor J ^a   Clagett, G Patrick ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

anticoagulation; bridgrg anticoagulation; dalteparin; LMWH; venous thromboembolism

Indexed keywords

EID: 84992782702     PISSN: 15310035     EISSN: None     Source Type: Journal    
DOI: 10.1177/153100350501700226     Document Type: Article

References (5)

1. Risk factors for stroke and efficacy of antithrombotic thetapy in atrial fibriillation: analysis of pooled data trom five randomized trials. Arch Intern Med 154: 1449-1457, 1994.
2. Mok CK Boey J, Wang R. et-al. Wairfarin virss dipsridaniole-aspirin and pentoxytfylline-aspuiri for the prevention of piosthetic heart vile thromhoemnlborsm: a prospective randomnized clinical trilal. Ciircaultion 72: 1059-1063, 1985.
3. Cannegietet SC. Rosendail FR, Briet E. Thromboeembolic anid bleeding complications in patients with mechanical heart valae pIostiheses. Circulation 89: 635-641 1994.
4. Kearon C. Haish J. Management of anticoagulation beftire and after elective Sugery. N Engl J Med 3136(21) 1506-1511, 1997.
5. Dunn AS. Turpie AG. Petlopeativatne management of patients receiving oral anticoagulants: a systematic review. Arch Intern Mtd 163: 901-908, 2003.